<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">AMC</journal-id><journal-title-group><journal-title>Advances in Material Chemistry</journal-title></journal-title-group><issn pub-type="epub">2331-012X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/AMC.2021.91002</article-id><article-id pub-id-type="publisher-id">AMC-39644</article-id><article-categories><subj-group subj-group-type="heading"><subject>AMC20210100000_56609837.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>化学与材料</subject></subj-group></article-categories><title-group><article-title>
 
 
  选择性组蛋白去乙酰化酶抑制剂的研究进展
  Progress in the Research of Selective 
  Histone deacetylase Inhibitors
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>立园</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>万</surname><given-names>勃亨</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>朱</surname><given-names>雍</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>唐</surname><given-names>伟方</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>中国药科大学理学院，江苏 南京</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>22</day><month>12</month><year>2020</year></pub-date><volume>09</volume><issue>01</issue><fpage>9</fpage><lpage>23</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    组蛋白去乙酰化酶(HDACs)参与组蛋白和非组蛋白赖氨酸残基乙酰化和去乙酰化动态平衡过程的调节，它的异常表达与癌症、神经性疾病、炎症、代谢异常等一系列疾病相关。HDAC具有多种亚型，且组织分布及生理功能均有差异，开发亚型选择性HDAC抑制剂可降低其毒副作用，并成为近年来的研究热点，目前已报道多种类型的选择性HDAC抑制剂。本文综述了现阶段选择性HDAC抑制剂的研究进展和潜在适应症。
    Histone deacetylases (HDACs) play a crucial role in regulating the balance of acetylation and deacetylation of lysine residues of histones and non-histone proteins, whose overexpression is closely associated with a great variety of cancers, neurological diseases, inflammatory diseases, metabolic disorders and so on. HDAC has lots of subtypes, and the tissue distribution and physiological functions are different, the development of subtype selective HDAC inhibitors can reduce its toxic and side effects, and has become a research hotspot in recent years. Several HDAC inhibitors have been reported so far. This review summarizes the current research progress and potential indications of selective HDAC inhibitors. 
  
 
</p></abstract><kwd-group><kwd>组蛋白去乙酰化酶，选择性抑制剂，潜在适应症, Histone deacetylase</kwd><kwd> Selective Inhibitors</kwd><kwd> Potential Indications</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>组蛋白去乙酰化酶(HDACs)参与组蛋白和非组蛋白赖氨酸残基乙酰化和去乙酰化动态平衡过程的调节，它的异常表达与癌症、神经性疾病、炎症、代谢异常等一系列疾病相关。HDAC具有多种亚型，且组织分布及生理功能均有差异，开发亚型选择性HDAC抑制剂可降低其毒副作用，并成为近年来的研究热点，目前已报道多种类型的选择性HDAC抑制剂。本文综述了现阶段选择性HDAC抑制剂的研究进展和潜在适应症。</p></sec><sec id="s2"><title>关键词</title><p>组蛋白去乙酰化酶，选择性抑制剂，潜在适应症</p></sec><sec id="s3"><title>Progress in the Research of Selective Histone deacetylase Inhibitors<sup> </sup></title><p>Liyuan Zhang, Boheng Wan, Yong Zhu, Weifang Tang<sup>*</sup></p><p>School of Science, China Pharmaceutical University, Nanjing Jiangsu</p><p><img src="//html.hanspub.org/file/2-3010099x4_hanspub.png" /></p><p>Received: Nov. 30<sup>th</sup>, 2020; accepted: Dec. 23<sup>rd</sup>, 2020; published: Jan. 4<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/2-3010099x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Histone deacetylases (HDACs) play a crucial role in regulating the balance of acetylation and deacetylation of lysine residues of histones and non-histone proteins, whose overexpression is closely associated with a great variety of cancers, neurological diseases, inflammatory diseases, metabolic disorders and so on. HDAC has lots of subtypes, and the tissue distribution and physiological functions are different, the development of subtype selective HDAC inhibitors can reduce its toxic and side effects, and has become a research hotspot in recent years. Several HDAC inhibitors have been reported so far. This review summarizes the current research progress and potential indications of selective HDAC inhibitors.</p><p>Keywords:Histone deacetylase, Selective Inhibitors, Potential Indications</p><disp-formula id="hanspub.39644-formula8"><graphic xlink:href="//html.hanspub.org/file/2-3010099x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/2-3010099x8_hanspub.png" /> <img src="//html.hanspub.org/file/2-3010099x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>乙酰化过程是一种常见的组蛋白翻译后修饰，主要由组蛋白乙酰基转移酶(Histone acetyltransferases, HATs)和组蛋白去乙酰化酶(Histone deacetylases, HDACs)共同调控。HDACs普遍存在于细菌、真菌和动物中，它的功能是去除组蛋白和非组蛋白乙酰化赖氨酸残基的N-乙酰基基团，阻止DNA转录，使得基因沉默。HDACs的高表达与癌症、神经退行性疾病、炎症、代谢异常等一些疾病相关 [<xref ref-type="bibr" rid="hanspub.39644-ref1">1</xref>]。因此，HDACs已经成为治疗这些疾病的潜在药用靶标，尤其是癌症方面。</p></sec><sec id="s6"><title>2. 组蛋白去乙酰化酶</title><p>目前在哺乳动物中发现有18种亚型的HDACs，根据它们与酵母HDAC 序列的同源性，可将其分为四类：I类包括HDAC (1、2、3和8)，普遍存在于细胞核中；II类包括IIa (HDAC4、5、7和9)和IIb (HDAC6和10)，IIa类主要存在于细胞质中，根据它们的磷酸化状态在细胞核质中穿梭往返，IIb类HDAC6主要存在于细胞质中，HDAC10在细胞核质中都存在；IV类包括HDAC11，在细胞核质都存在；Ⅲ类也叫做sirtuins，是NAD+依赖的HDAC [<xref ref-type="bibr" rid="hanspub.39644-ref2">2</xref>]。而I、II和IV类是Zn<sup>2+</sup>依赖的HDAC。</p><p>HDAC1在胃癌、前列腺癌、卵巢癌中异常表达，HDAC3在卵巢癌和结肠癌中异常表达，HDAC2在结肠癌中异常表达 [<xref ref-type="bibr" rid="hanspub.39644-ref1">1</xref>]。除此之外，HDAC8在T细胞淋巴瘤、成神经细胞瘤及德朗日综合征(Cornelia de Lange Syndrome, CdLS)中高表达 [<xref ref-type="bibr" rid="hanspub.39644-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.39644-ref4">4</xref>]。与I类HDACs不同，II类HDACs (HDAC4、5、7和9)与部分信号转导通路有关 [<xref ref-type="bibr" rid="hanspub.39644-ref5">5</xref>]。此外，HDAC6能催化非组蛋白底物，如α-微管蛋白，皮质肌动蛋白和HSP90，在和癌症相关的细胞增殖、迁移、侵袭和有丝分裂方面发挥着重要的作用 [<xref ref-type="bibr" rid="hanspub.39644-ref6">6</xref>]。HDAC11作为IV类HDAC的唯一成员，与由致癌激酶JAK2驱动的骨髓增殖性肿瘤(MPN)细胞的增殖和生存相关 [<xref ref-type="bibr" rid="hanspub.39644-ref7">7</xref>]。</p></sec><sec id="s7"><title>3. 组蛋白去乙酰化酶抑制剂</title><p>四种HDAC抑制剂(HDACi)，即伏立诺他(vorinostat, SAHA)、贝利司他(belinostat, PXD101)、帕比司他(panobinostat, LBH589)和罗米地辛(romidepsin, FK228)已经被美国FDA批准分别用于治疗皮肤T 细胞淋巴瘤(CTCL)，复发及难治性外周T细胞淋巴瘤(PTCL)，多发性骨髓瘤(MM)，而西达本胺(chidamide, CS055)也已经被中国NMPA批准，用于治疗复发或难治性外周T细胞淋巴瘤 [<xref ref-type="bibr" rid="hanspub.39644-ref2">2</xref>]，另外还有多个HDACi处于临床试验阶段。多数HDACi的结构包含三个药效团：帽子结构(Cap区)，与HDAC活性位点入口边缘处的氨基酸残基作用；锌离子结合基团(ZBG)，与位于活性位点口袋底部的催化锌离子螯合；以及连接Cap区和ZBG区的连接部分(Linker区)，作用于活性位点的疏水性通道 [<xref ref-type="bibr" rid="hanspub.39644-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.39644-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.39644-ref10">10</xref>] (图1，以伏立诺他为例)。</p><p>图1. HDACi的结构</p><p>根据HDACi的化学结构，可将其主要分为四类：异羟肟酸类(如伏立诺他)、苯甲酰胺类(如西达本胺)、环肽类(如罗米地辛)、和脂肪酸类(如2-丙基戊酸)。除此之外，近几年出现的酰肼类、异亚硝基类、邻苯二酚类、磺胺类等ZBG基团作为潜在的药效团值得科学家们进一步探索 [<xref ref-type="bibr" rid="hanspub.39644-ref2">2</xref>]。广谱HDACi普遍存在一些副作用，如恶心、呕吐、疲劳和心脏毒性等，限制了它们的应用。选择性HDACi的出现不但成为研究HDAC亚型功能的一种化学工具，而且也提供一种相对于广谱HDACi更加安全有效的化疗方法。本文将对选择性HDACi的研究进展和潜在适应症进行综述。</p></sec><sec id="s8"><title>4. 选择性HDACi</title><sec id="s8_1"><title>4.1. I类选择性HDACi</title><sec id="s8_1_1"><title>4.1.1. 苯甲酰胺类</title><p>Entinostat(MS-275) (1，图2)是一个有效的I类选择性HDACi，它可以抑制HDAC1,3和8，IC<sub>50</sub>分别是0.368 μM，0.501 μM和63.4 Μm [<xref ref-type="bibr" rid="hanspub.39644-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.39644-ref12">12</xref>]，目前Entinostat作为表观遗传学疗法，用来治疗多种癌症如乳腺癌和非小细胞肺癌。</p><p>Mocetinostat (MGCD0103) (2，图2)是一个新型的选择性HDAC(I/IV)抑制剂，可以抑制HDAC1,2,3和11。Mocetinostat在体外对人类肿瘤细胞表现出有效和广谱的抗增殖活性 [<xref ref-type="bibr" rid="hanspub.39644-ref13">13</xref>]。目前，Mocetinostat正用于急性粒细胞白血病、膀胱癌、非小细胞肺癌等疾病的研究，已进入II期临床试验。</p><p>Tacedinaline (CI994) (3，图2)是一个有效的抗肿瘤的选择性I类HDACi [<xref ref-type="bibr" rid="hanspub.39644-ref14">14</xref>]。CI994对宫颈癌HeLa细胞中高表达的HDAC1和3具有选择性抑制作用 [<xref ref-type="bibr" rid="hanspub.39644-ref15">15</xref>]。目前CI994正用于治疗非小细胞肺癌、胰腺癌的研究，已进入II期临床试验。</p><p>4-SC202 (4，图2)是一个有效的选择性I类HDACi，选择性抑制HDAC1,2和3。在宫颈癌HeLa和结肠癌RKO细胞系体外实验中，4-SC202可以呈剂量依赖性的方式上调组蛋白H3乙酰化水平 [<xref ref-type="bibr" rid="hanspub.39644-ref16">16</xref>]。4SC-202用于胃肠癌的治疗，已经进入临床试验。</p><p>RG2833 (5，图2)是一个可以透过血脑屏障的HDACi，对HDAC1和3的IC<sub>50</sub>分别是60 nM和50 nM。在神经元细胞中，RG2833增加了Friedreich Ataxia(FXN)mRNA和蛋白质的表达，并伴随着基因表观遗传状态的变化。在病人血液PBMC细胞中，RG2833抑制HDAC作用并加强组蛋白H3K9的乙酰化 [<xref ref-type="bibr" rid="hanspub.39644-ref17">17</xref>]。</p><p>BG45 (6，图2)是一个选择性HDAC3抑制剂，对HDAC1、2和6抑制活性明显降低。BG45单独或与硼替佐米联用可以抑制大鼠异种移植人多发性骨髓瘤(MM)的增长 [<xref ref-type="bibr" rid="hanspub.39644-ref18">18</xref>]。研究发现BG45抑制HDAC活性时，可以下调HO-1的水平，可用于HO-1高表达的MM治疗；它可以使MM细胞阻滞在G0/G1期，抑制细胞的增殖，并通过增加促凋亡Bcl-2蛋白家族的表达，激活PARP；同时也发现BG45介导HO-1的表达，并干扰JAK2/STAT3信号传导途径诱导MM细胞凋亡 [<xref ref-type="bibr" rid="hanspub.39644-ref19">19</xref>]。</p><p>RGFP966 (7，图2)是IC<sub>50</sub>为80 nM的选择性HDAC3抑制剂 [<xref ref-type="bibr" rid="hanspub.39644-ref20">20</xref>]，对其他亚型在浓度高达15 uM时也没有抑制作用。研究发现RGFP966作为选择性HDAC3抑制剂在体内能够预防缺血性脑损伤；它能抑制体外培养的小神经胶质细胞AIM2炎性小体活性，可能与调节STAT1的磷酸化和乙酰化水平有关；在实验小鼠中风模型中，RGFP966能减少炎性小体的表达 [<xref ref-type="bibr" rid="hanspub.39644-ref21">21</xref>]。</p><p>对CI-994进行结构优化，得到一个选择性HDAC3抑制剂BRD3308 (8，图2)，对HDAC1-3的IC<sub>50</sub>分别是1.08，1.15和0.064 nM。BRD3308抑制炎症性细胞因子(如糖脂毒性应激)诱导的胰岛β细胞的凋亡，增加功能性胰岛素的释放。相对于HDAC1、2抑制剂对人巨核细胞分化的毒性，BRD3308对巨核细胞的分化无影响，因此，选择性抑制HDAC3可能会成为一种保护胰岛β细胞的有效方式，使之避免糖尿病中的炎症性细胞因子和营养过剩带来的害处 [<xref ref-type="bibr" rid="hanspub.39644-ref22">22</xref>]。</p><p>图2. 苯甲酰胺类HDACi</p><p>BRD6688 (9，图2)是一个选择性HDAC1-3抑制剂，IC<sub>50</sub>分别是21 nM，100 nM和11.48 μM。研究发现在CK-p25的小鼠神经性疾病模型中，BRD6688可以增加小鼠神经元细胞和海马体CA1神经元细胞组蛋白H4K12和H3K9的乙酰化水平 [<xref ref-type="bibr" rid="hanspub.39644-ref23">23</xref>]。</p><p>5-噻吩基取代的2-氨基苯甲酰胺类选择性HDAC1、2抑制剂K-560 (10，图2)对神经有保护作用，之后合成了一系列K-560相关的化合物。这些化合物显示出有效的HDAC1,2抑制活性，并且对HDAC1表现出10~26倍的选择性较HDAC2。其中化合物K-856 (11，图2)和先导物K-560都有潜在神经保护活性，且活性高于罗米地辛，与MS-275相似。构效关系(SAR)表明，将2,3或2,5-二酮哌嗪单环引入到5-芳基-2-氨基苯甲酰胺类化合物骨架中有潜在的神经保护作用 [<xref ref-type="bibr" rid="hanspub.39644-ref24">24</xref>]。</p><p>研究发现抗雌激素药物和HDACi联用对乳腺癌有抗增殖作用，Mendoza等 [<xref ref-type="bibr" rid="hanspub.39644-ref25">25</xref>] 将抗雌激素药物ICI-164,384的药效团引入到HDACi苯甲酰胺结构中，得到的化合物RMS-162 (12，图2)有着潜在的HDAC3抑制活性(IC<sub>50</sub>为3.18 uM)，同时抗雌激素活性良好(Luciferase IC<sub>50</sub> = 0.72 uM, BRET IC<sub>50</sub> = 0.2 1uM)。除此之外，RMS-162还有较好的乳腺癌细胞MCF-7抑制活性，IC<sub>50</sub>为1.9 uM。</p><p>MI192 (13，图2)对HDAC2和3的IC<sub>50</sub>分别为30和16nM。经过NCI60个肿瘤细胞株的普筛，发现MI192对一些白血病细胞株有较好的抑制活性(如HL-60, CCRF-CEM, MOLT-4, RPMI-8226和K562)，同时，MI192可以诱导一些白血病细胞(HL-60, U937和Kasumi-1)的分化和凋亡。与MS-275相比，MI-192表现出高于其2-3倍的白血病细胞抗增殖活性 [<xref ref-type="bibr" rid="hanspub.39644-ref26">26</xref>]。</p><p>CXD101 (14，图2)是一个新型选择性I类HDACi，对HDAC1-3的IC<sub>50</sub>为63 nM，570 nM和550 nM。该药对结肠癌、肺癌、非霍奇金淋巴瘤和骨髓瘤细胞的IC<sub>50</sub>值为0.2~15 uM。当给药剂量为50 mg/kg时，CXD101可以抑制小鼠体内异种移植肺癌(A549细胞)和结肠癌(HT29)肿瘤模型的增长，同时伴随着组蛋白乙酰化水平的上调以及HDAC活性的降低 [<xref ref-type="bibr" rid="hanspub.39644-ref27">27</xref>]。</p></sec><sec id="s8_1_2"><title>4.1.2. 环肽类</title><p>Largazole (15，图3)是一个大环缩酚肽类天然产物，对HDAC1表现出较好的活性和选择性。它对人乳腺癌细胞MDA-MB-231和人骨肉瘤细胞U2OS表现出纳摩尔级抗增殖活性，GI<sub>50</sub>分别是7.7和55 nM，对正常细胞无影响。Largazole是一个前药，经水解得到游离的硫醇基与锌离子螯合，具有较高的I类HDAC抑制活性 [<xref ref-type="bibr" rid="hanspub.39644-ref28">28</xref>]。</p><p>Romidepsin (FK228) (16，图3)，是不含环氧酮的双环四肽类化合物，是用十五元的大环二硫环桥接的十六元缩酚酞。从紫色杆菌中第一次分离和发现了Romidepsin，它是一个有效和选择性的I类HDACi，对HDAC1、2、4和6的IC<sub>50</sub>分别是36, 47, 510和14000 nM。Romidepsin的SAR显示它的脱氢丁酸侧链对HDAC的抑制活性不是必要的，而大环的限制构象对活性是必要的 [<xref ref-type="bibr" rid="hanspub.39644-ref29">29</xref>]。</p><p>Spiruchostatin A和B，是从假单胞菌中提取分离而得到的。目前在临床上用于癌症的治疗。Spiruchostatin A (17，图3)是选择性I类HDACi，抑制乳腺癌细胞的增长，IC<sub>50</sub>约在10nM左右；Spiruchostatin B (18，图3)作为HDACi用于白血病的治疗；Spiruchostatin C (19，图3)，从伯克霍尔德菌分离出，对HDAC1和HDAC8展现出较好的抑制作用。</p><p>Thailandepsins和burkholdacs (20~22，图3)是细菌的产物，从伯克霍尔德氏菌E264发酵培养液中分离出，对I类HDAC表现出潜在的抑制活性。</p><p>1996年Sandra等 [<xref ref-type="bibr" rid="hanspub.39644-ref17">17</xref>] 发现一种天然产物Apicidin (23，图3)具有广谱的抗寄生虫活性，研究表明，是由于对HDAC的抑制而发挥作用。后续研究发现，Apicidin及其类似物可以作为金黄色葡萄球菌agr抑制剂，通过群体感应抑制作用和增加中性粒细胞(PMNs)的应答对抗耐甲氧西林金黄色葡萄球菌(MRSA)，加强宿主细胞的防御作用 [<xref ref-type="bibr" rid="hanspub.39644-ref30">30</xref>]。</p></sec><sec id="s8_1_3"><title>4.1.3. 异羟肟酸类</title><p>Quisinostat (JNJ-26481585) [<xref ref-type="bibr" rid="hanspub.39644-ref31">31</xref>] (24，图4)是一个异羟肟酸类I类HDAC抑制剂，HDAC1-3的IC<sub>50</sub>分别是0.11, 0.33和4.8 nM。它可以通过抑制HDAC1进而诱导p21<sup>waf1,cip1</sup>的表达，诱导肿瘤组织中组蛋白H3乙酰化以及体外人结肠癌细胞的凋亡。目前，Quisinostat处在II期临床试验中，用于输卵管癌、卵巢癌的治疗。</p><p>图3. 环肽类HDACi</p><p>Su等 [<xref ref-type="bibr" rid="hanspub.39644-ref32">32</xref>] 通过高通量筛选，从16320个化合物中发现了Scriptaid (25，图4)，对I类HDAC具有潜在的抑制活性。研究发现Scriptaid可以增加神经胶质瘤细胞组蛋白H3和H4的乙酰化水平，依赖于Ras的高表达诱导胶质瘤细胞的凋亡，而Ras的促凋亡作用是通过JNK通路的激活，实验显示用Scriptaid治疗后胶质瘤细胞的p38MAPK和JNK活性有所提高。同时Scriptaid参与肿瘤细胞周期和肿瘤损伤应答修复蛋白的调节也是依赖于JNK的活性。JNK是调节端粒酶活性的关键蛋白，但是Scriptaid抑制胶质瘤端粒酶的活性不是依赖于JNK的活性。因此，无论JNK抑制剂是否存在，用Scriptaid治疗后，细胞端粒酶活性的减少没有受到影响。因此，Scriptaid有望成为治疗多形性成胶质细胞瘤的药物 [<xref ref-type="bibr" rid="hanspub.39644-ref33">33</xref>]。</p><p>Droxinostat (NS41080) (26，图4)是一个I/II类HDACi，对HDAC3, HDAC6和8的IC<sub>50</sub>分别是2.47，1.46 μM和16.9 μM [<xref ref-type="bibr" rid="hanspub.39644-ref34">34</xref>]。c-FLIP是一个抗凋亡蛋白，它可以拮抗半胱天冬酶-8介导的凋亡。用Droxinostat给药，前列腺癌细胞22Rv1和LNCaP中的c-FLIP表达减少，细胞凋亡增加，并且能够影响比卡鲁胺对AR表达的胰腺癌细胞的敏感性，使得用比卡鲁胺治疗胰腺癌22Rv1和LNCaP细胞时加强或保持凋亡的最高水平 [<xref ref-type="bibr" rid="hanspub.39644-ref35">35</xref>]。</p><p>PCI-34051 (27，图4)是一个选择性HDAC8抑制剂，Ki值为10 nM，较对HDAC1-3, 6,和10的选择性高200倍。PCI-34051能够诱导特殊细胞的半胱天冬酶介导的凋亡，如源自T细胞淋巴瘤和白血病的细胞系。对于正常的细胞如外周血单核细胞PBMCs或纤维母细胞，PCI-34051不会影响细胞组蛋白或微管蛋白的乙酰化水平，也不会抑制和诱导正常细胞的增殖和凋亡。PCI-34051较广谱HDACi毒性有所降低，有望成为治疗T细胞衍生的肿瘤药物 [<xref ref-type="bibr" rid="hanspub.39644-ref36">36</xref>]。</p><p>图4. 异羟肟酸类HDACi</p><p>Suzuki等 [<xref ref-type="bibr" rid="hanspub.39644-ref37">37</xref>] 用点击化学方法从151个三氮唑库中发现了选择性HDAC8抑制剂NCC149 (28，图4)，HDAC8的IC<sub>50</sub>为0.07 uM。之后对NCC149进行结构优化，合成一系列杂环类化合物，都表现出HDAC8抑制活性，其中化合物29 (图4) (IC<sub>50</sub>为0.15 uM)剂量依赖性诱导HDAC8底物黏连蛋白乙酰化，而其它HDAC底物如组蛋白H3K9或微管蛋白乙酰化没有明显提高，显示化合物29是高选择性的HDAC8抑制剂。而且化合物29抑制T细胞淋巴瘤活性高于NCC149。</p><p>AR-42为口服有效的HDACi，在临床试验中用于多发性骨髓瘤、白血病、淋巴瘤的治疗。Tng等 [<xref ref-type="bibr" rid="hanspub.39644-ref38">38</xref>] 发现了AR-42的类似物，包含通过季碳原子连接的环烷基，对人的I类HDAC活性提高40倍，并且对五种人的癌细胞的细胞活性提高25倍(如化合物JT86 (30，图4)，对HDAC1的IC<sub>50</sub>为0.7nM)。JT86促进黑色素瘤细胞MM96L组蛋白H4的乙酰化水平的积累，活性比AR-42的R构型高9倍。JT86及AR-42的类似物可能会比AR-42更具有应用前景，并且在AR-42治疗的疾病(如癌症、寄生虫感染及炎症)方面也发挥作用。</p><p>经过合理的药物设计，构象限制等方法，研究发现苯甲酰苯胺类折叠化合物可以选择性的与HDAC8的催化通道结合。其中化合物MMH371 (31，图4)，MMH409 (32，图4)，和MMH410 (33，图4)对HDAC8表现出较高的活性和选择性(IC<sub>50</sub>分别为66, 23和66 nM)，并且对HDAC8的抑制活性较其它HDAC高于410倍。将苯甲酰苯胺类化合物与人的HDAC8进行对接的试验和计算进行分析发现，该类化合物采用能量较低的L型构象，有利于实现对HDAC8的选择性 [<xref ref-type="bibr" rid="hanspub.39644-ref39">39</xref>]。</p><p>NBM-T-L-BMX-OS01 (BMX) (34，图4)来源于蛇床子素(一种中药成分)的半合成，是有效的选择性HDAC8抑制剂。该药可以透过血脑屏障且没有神经毒性，BMX给药的大鼠较SAHA在水迷宫训练实验中表现出记忆获取能力以及在探针试验中获得更好的记忆恢复能力，并且观察到在被动单向规避试验中表现出不错的记忆保持能力 [<xref ref-type="bibr" rid="hanspub.39644-ref40">40</xref>]。</p><p>CHR-3996 (35，图4)是一个选择性I类HDACi，IC<sub>50</sub>为8 nM，对HDAC1的选择性较HDAC6高700倍。当静脉注射给药1 mg和口服10 mg时，该药在种属狗和大鼠中的生物利用度可达到40%和27%。在实体瘤和血液瘤的抗增殖实验中，CHR-3996抑制活性范围在31~750 nM之间，活性高于SAHA5-20倍 [<xref ref-type="bibr" rid="hanspub.39644-ref41">41</xref>]。</p></sec></sec><sec id="s8_2"><title>4.2. II类选择性HDACi</title><sec id="s8_2_1"><title>4.2.1. IIa类选择性HDACi</title><p>LMK-235 (36，图5)是选择性II类(HDAC4和5)HDACi，以烷氧基酰胺基作为linker的异羟肟酸类HDACi。疏水性二甲基苯基作为Cap区，增加了LMK-235对II类HDAC的选择性。Marek等 [<xref ref-type="bibr" rid="hanspub.39644-ref42">42</xref>] 合成和评估了该药的HDAC抑制活性和对顺铂敏感及耐受的癌细胞生物活性。LMK-235对HDAC4和5的IC<sub>50</sub>分别为11.9，4.22 nM。LMK-235与SAHA相比对细胞水平的pan-HDAC测试，表现出相似的抑制活性，而对人类癌症细胞系A2780, Cal27, Kyse510和MDA-MB231细胞毒性有所提高。LMK-235与顺铂联合用药，比伏立诺他和顺铂联用效果要好。</p><p>TMP269和195 (37和38，图5)是II类选择性非异羟肟酸类HDACi，它们的ZBG被三氟甲基噁二唑基(TFMO)取代。而且，TFMO这个基团作为非金属离子螯合基团，通过弱静电与催化锌离子作用。TFMO系列化合物较异羟肟酸类化合物脱靶效应有所降低。凝集素(PHA)激发的人外周血单核细胞(PBMC)的基因表达谱研究间接证明了这类化合物的高选择性。在这些细胞中，SAHA调节4556个基因的表达，而TMP195仅仅调节76个基因。这个发现与在纤维母细胞中观察到的一致，HDAC4也调节76个基因。为进一步研究TFMO系列化合物的转录组学特征，Lobera等纯化了来源于凝集素(PHA)激发的人外周血单核细胞(PBMC)中的T细胞(CD3+)，B细胞(CD19+)和单核细胞(CD14+)，并用TMP195分别给药。T细胞和B细胞对TMP195敏感性较低(17和36个基因被分别调节)，相反该药对单核细胞的作用是显著的(587个基因)。该化合物干扰单核细胞到巨噬细胞M-CSF(巨噬细胞群刺激因子)诱导的分化。这些发现证明选择性IIa类HDACi可以作为治疗免疫性疾病的候选药物 [<xref ref-type="bibr" rid="hanspub.39644-ref43">43</xref>]。</p><p>Tasquinimod (39，图5)是抗血管生成的选择性HDAC4抑制剂。研究显示该药可降低血管密度，但机制尚不明确。在携带人前列腺癌细胞异种移植的小鼠模型中，发现Tasquinimod可以加强多西他赛的抗血管生成作用以及抗雄激素作用。Tasquinimod目前在I/II期临床实验中用于癌症的治疗 [<xref ref-type="bibr" rid="hanspub.39644-ref44">44</xref>]。</p><p>MC1568 和MC1575 (40和41，图5)是II类选择性HDACi，特异性抑制HDAC4和6 [<xref ref-type="bibr" rid="hanspub.39644-ref43">43</xref>] [<xref ref-type="bibr" rid="hanspub.39644-ref45">45</xref>]。它们是I类HDACi APHAs的衍生物，表现出对IIa类HDAC较优的抑制活性，该选择性体现在对linker区的修饰。相比于经典的I类HDACi，这类化合物的细胞毒性作用降低。此外，MC1568和MC1575对黑色素瘤细胞和ER+的乳腺癌细胞表现出抑制作用。该类化合物通过诱导Cdk抑制剂p21/Cip1/Waf1使癌症细胞停滞在细胞周期的G1期，从而发挥出抗增殖作用。</p><p>图5. IIa类选择性HDACi</p></sec><sec id="s8_2_2"><title>4.2.2. IIb类选择性HDACi</title><p>Tubacin (42，图6)是第一个发现的选择性HDAC6抑制剂，其IC<sub>50</sub>是HDAC1的350倍 [<xref ref-type="bibr" rid="hanspub.39644-ref46">46</xref>]。Tubacin能诱导α-微管蛋白(α-tubulin)乙酰化。该药与SAHA有着同样的ZBG区和linker区，而较复杂的Cap区使其对HDAC6的选择性起关键作用。但是由于较高的脂溶性和较复杂的合成路线使得Tubacin主要成为研究的工具药物使用 [<xref ref-type="bibr" rid="hanspub.39644-ref47">47</xref>]。</p><p>Tubastatin A (43，图6)是一个有效的选择性HDAC6抑制剂，IC<sub>50</sub>值为15 nM。该药除了比HDAC8的选择性高于57倍，对其它亚型的HDAC选择性都高于1000倍。在皮质神经元细胞测试中，发现Tubastatin A能提高α-微管蛋白乙酰化水平，而不影响组蛋白乙酰化水平，这符合高选择HDAC6抑制剂的作用机制特点。在对抗皮质神经元细胞中谷胱甘肽消耗诱导的氧化应激反应的影响，Tubastatin A发挥出剂量依赖性的保护作用。Tubastatin A在测试的浓度条件下单独给药不表现出神经毒性，预示Tubastatin A及其类似物对神经退行性疾病的潜在应用 [<xref ref-type="bibr" rid="hanspub.39644-ref48">48</xref>]。</p><p>Ricolinostat (ACY-1215) (44，图6)作为选择性HDAC6抑制剂，其IC<sub>50</sub>值为5nM，它对HDAC6的抑制活性比HDAC1-3高于10倍。Ricolinostat目前作为单一疗法或与其它靶标活性成分联合用药，在临床I/II期用于复发及难治性多发性骨髓瘤和淋巴瘤的治疗。</p><p>Citarinostat (ACY-241) (45，图6)是一个可口服的选择性的HDAC6抑制剂，目前在临床I期用于多发性骨髓瘤的治疗。与Ricolinostat相似，Citarinostat较非选择性HDACi降低了毒副作用，同时又表现出一定的抗癌活性。</p><p>ACY-738 和ACY-775 (46和47，图6)，对HDAC6的抑制活性可达到较低的纳摩尔级水平，并且抑制活性较I类HDAC高60-1500倍。此外，它们可以明显提高脑内α-微管蛋白乙酰化水平和刺激小鼠在新的陌生环境的试探性行为。虽然不能诱导组蛋白的乙酰化，但是，ACY-738和ACY-775与其它的HDAC抑制剂如SAHA和MS-275一样，在小鼠尾巴悬挂测试和社交挫败案例中表现出抗抑郁活性。这些发现都预示着HDAC6在中枢神经系统(CNS)的潜在应用，以及可以作为抗抑郁药物研究的新靶标 [<xref ref-type="bibr" rid="hanspub.39644-ref49">49</xref>]。</p><p>CAY10603 (48，图6)是一个强效的HDAC6抑制剂，IC<sub>50</sub>值为2pM，对HDAC6的抑制活性较其它亚型高200倍。在对胰腺癌细胞抗增殖活性中，CAY10603对Mia Paca-2和Panc04.03细胞系的IC<sub>50</sub>值都为100 nM，对HupT3细胞的IC<sub>50</sub>值为300nM。CAY10603对正常细胞HMEC和HPDE6c7的抑制活性小于1 uM [<xref ref-type="bibr" rid="hanspub.39644-ref50">50</xref>]。</p><p>HPOB (49，图6)是一个选择性HDAC6抑制剂，IC<sub>50</sub>为56nM，较其它亚型的HDAC抑制活性高于30倍。HPOB抑制正常和转化细胞的生长，而不诱导细胞的死亡。同时HPOB加强DNA损伤抗癌药物对转化而非正常细胞的功效。而且HPOB不会抑制HDAC6的泛素结合活性 [<xref ref-type="bibr" rid="hanspub.39644-ref51">51</xref>]。</p><p>Nexturastat A (50，图6)选择性抑制HDAC6，IC<sub>50</sub>为5nM，对HDAC6的抑制活性较HDAC1高600倍。与LBH589相比，Nexturastat A诱导小鼠黑色素瘤B16细胞死亡的活性低于该药100倍。SAR显示在化合物脲基的氮原子上引入取代基，使得化合物成为具有分支的linker区，提高了对HDAC6的活性和选择性 [<xref ref-type="bibr" rid="hanspub.39644-ref52">52</xref>]。</p><p>TCS HDAC620b (51，图6)是一个有效的选择性HDAC6抑制剂，在结肠癌细胞HCT-116中，TCS HDAC620b明显提高α-微管蛋白乙酰化水平，并呈剂量依赖性，同时不明显影响组蛋白H4乙酰化水平，显示该药对HDAC6具有选择性抑制作用。将TCS HDAC620b (5 uM)和紫杉醇(0.03 μM)联用对HCT-116细胞的生长抑制率大约50% [<xref ref-type="bibr" rid="hanspub.39644-ref46">46</xref>]。</p><p>WT161 (52，图6)是一个口服有活性的选择性HDAC6抑制剂，IC<sub>50</sub>值为0.4nM。该药与蛋白酶体抑制剂硼替佐米联用可引起明显的多泛素化蛋白和细胞压力的积聚，之后伴随着半胱天冬酶的激活和凋亡。这两种药物联用，在对硼替佐米耐受的细胞中是有效的，而且在骨髓基质细胞中，联用可以调节多发性骨髓瘤细胞药物产生的耐药性 [<xref ref-type="bibr" rid="hanspub.39644-ref53">53</xref>]。</p><p>NQN-1 (53，图6)是一种消炎药，可选择性抑制HDAC6,IC<sub>50</sub>值为5.54 uM，对其它亚型的HDAC没有抑制作用。NQN-1选择性的提高微管蛋白乙酰化水平，而不提高组蛋白H3和H4的水平，但是该药与tubastatin A 和tubacin类似，可以降低组蛋白H4的水平。除此之外，NQN-1可以选择性杀死白血病细胞而不影响正常外周血液单核细胞 [<xref ref-type="bibr" rid="hanspub.39644-ref54">54</xref>]。</p><p>在一系列无Cap区的新型选择性HDAC6抑制剂中，发现化合物BRD9757 (54，图6)的IC<sub>50</sub>值为30 nM。BRD9757可以提高细胞中微管蛋白乙酰化水平，而不影响组蛋白乙酰化水平，体现了该药对HDAC6的选择性作用。之后作者发现异羟肟酸的α位碳原子sp<sup>2</sup>杂化可以提高活性，而体积较小的无Cap区的环烯基基团可以提高对HDAC6的选择性 [<xref ref-type="bibr" rid="hanspub.39644-ref55">55</xref>]。</p><p>Kozikowski等 [<xref ref-type="bibr" rid="hanspub.39644-ref56">56</xref>] 报道了四氢喹啉类选择性HDAC6抑制剂SW-100 (55，图6)，该药表现出较好的大脑渗透性，对HDAC6表现出较低的纳摩尔级抑制活性(IC<sub>50</sub> = 2.3 nM)，选择性较其它亚型高1000倍。SW-100可以上调微管蛋白的乙酰化水平而不影响组蛋白的乙酰化，并且可以选择性恢复脆性X综合征(FXS)Fmr1<sup>–/–</sup>小鼠模型海马体受损的α-微管蛋白的乙酰化水平。SW-100可以改善Fmr1<sup>–/–</sup>小鼠的一些记忆和学习损伤，为罕见病的治疗提供了一种基于HDAC6靶点的治疗方法。</p><p>SS-208 (56，图6)为异噁唑-3-异羟肟酸类选择性HDAC6抑制剂，SS-208与DrHDAC6的晶体复合物表明，与活性位点Zn<sup>2+</sup>双齿螯合不同于以往与HDAC6晶体复合物单齿螯合的苯基异羟肟酸类抑制剂。虽然该药体外对小鼠SM1黑色素瘤细胞的活性较低，但是SS-208可以显著降低小鼠同源黑色素瘤模型中肿瘤的生长。并且发现SS-208的抗肿瘤活性主要是由免疫相关的抗肿瘤活性介导，通过增加肿瘤微环境CD8+ 和 NK+ T 细胞的浸润，以及提高巨噬细胞M1与M2的比值来发挥抗肿瘤活性 [<xref ref-type="bibr" rid="hanspub.39644-ref57">57</xref>]。</p><p>Barbara等 [<xref ref-type="bibr" rid="hanspub.39644-ref58">58</xref>] 设计并合成了五元杂环类选择性HDAC6抑制剂，其中化合物ITF3756 (57，图6)对HDAC6表现出较高的活性和选择性(HDAC6 IC<sub>50</sub> = 17 nM)。该药可明显提高α-tubulin的乙酰化水平而不影响组蛋白H3，并且在体外表现低毒性，在体内ITF3756的最大耐受剂量(MTD)高于50 mg/kg，体现了ITF3756的体内低毒性。ITF3756在小鼠体内代谢稳定、口服可利用，表现出可接受的药代动力学性质。而且这类化合物在体外可调控调节性T细胞的功能，为自身免疫疾病的治疗或器官移植提供了一种有效的方法。</p><p>图6. IIb类选择性HDACi</p></sec></sec><sec id="s8_3"><title>4.3. IV类选择性HDACi</title><p>N-羟基-2-芳基异吲哚啉-4-羧酰胺类化合物为有效和选择性的HDAC11抑制剂，这类抑制剂的发现、合成以及构效关系研究已被报道。FT895 (58，图7)为此类化合物的类似物，对HDAC11 (IC<sub>50</sub> = 3 nM)的抑制活性较其它HDAC亚型高1000倍。FT895表现出较好的PK性质，t<sub>1/2</sub>为10.2 h，生物利用度为81%，这对HDAC11的生物学研究和疾病的治疗提供了一种有效的方法 [<xref ref-type="bibr" rid="hanspub.39644-ref59">59</xref>]。</p><p>Son等 [<xref ref-type="bibr" rid="hanspub.39644-ref60">60</xref>] 采用药物合理设计的方法，发现了化合物SIS17 (59，图7)，活性虽然比FT895低，但是对HDAC11的选择性较高。在细胞水平上该药可抑制HDAC11的底物丝氨酸羟甲基转移酶2(SHMT2)肉豆蔻酰化而不抑制其它HDAC。</p><p>图7. IV类选择性HDACi</p></sec></sec><sec id="s9"><title>5. 结语</title><p>数十年来，对表观遗传学的研究和关注越来越多。HDAC作为表观遗传学过程中重要的靶标之一，在癌症等疾病方面扮演着不可或缺的角色。随着5个HDAC抑制剂的上市，以及多个泛HDACis和选择性HDACi进入临床的使用，HDACs显然已作为新型抗癌药物的重要靶标。然而泛HDACi普遍存在着一些副作用，所以，寻找亚型选择性的HDACi已成为近五年来的热点话题。相信随着科学家们的不断努力，会有越来越多的高效、低毒HDACi应用于癌症及其它疾病的治疗。</p></sec><sec id="s10"><title>文章引用</title><p>张立园,万勃亨,朱 雍,唐伟方. 选择性组蛋白去乙酰化酶抑制剂的研究进展Progress in the Research of Selective Histone deacetylase Inhibitors[J]. 材料化学前沿, 2021, 09(01): 9-23. https://doi.org/10.12677/AMC.2021.91002</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39644-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, C., Dong, H., Xu, Q., et al. (2020) Histone Deacetylase (HDAC) Inhibitors in Cancer: A Patent Review (2017-Present). Expert Opinion on Therapeutic Patents, 30, 263-274. https://doi.org/10.1080/13543776.2020.1725470</mixed-citation></ref><ref id="hanspub.39644-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Sultana, F., Manasa, K.L., Shaik, S.P., et al. (2019) Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update. Current Medicinal Chemistry, 26, 7212-7280.  
https://doi.org/10.2174/0929867325666180530094120</mixed-citation></ref><ref id="hanspub.39644-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, H., Shang, Y.P., Chen, H.Y., et al. (2017) Histone Deacetylase Function as Novel Potential Therapeutic Targets for Cancer. Hepatology Research, 47, 149-159. https://doi.org/10.1111/hepr.12757</mixed-citation></ref><ref id="hanspub.39644-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, C., Zang, J., Ding, Q., et al. (2018) Discovery of Meta-Sulfamoyl N-Hydroxybenzamides as HDAC8 Selective Inhibitors. European Journal of Medicinal Chemistry, 150, 282-291. https://doi.org/10.1016/j.ejmech.2018.03.002</mixed-citation></ref><ref id="hanspub.39644-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Parra, M. (2015) Class IIa HDACs—New Insights into Their Functions in Physiology and Pathology. The FEBS Journal, 282, 1736-1744. https://doi.org/10.1111/febs.13061</mixed-citation></ref><ref id="hanspub.39644-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Li, T., Zhang, C., Hassan, S., et al. (2018) Histone Deacetylase 6 in Cancer. Journal of Hematology &amp; Oncology, 11, 111. https://doi.org/10.1186/s13045-018-0654-9</mixed-citation></ref><ref id="hanspub.39644-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Yue, L., Sharma, V., Horvat, N.P., et al. (2020) HDAC11 Deficiency Disrupts Oncogene-Induced Hematopoiesis in Myeloproliferative Neoplasms. Blood, 135, 191-207. https://doi.org/10.1182/blood.2019895326</mixed-citation></ref><ref id="hanspub.39644-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Thomas, A.M., David, J.W. and Sandro, B. (2003) Histone Deacetylase Inhibitors. Journal of Medicinal Chemistry, 46, 5097-5116. https://doi.org/10.1021/jm0303094</mixed-citation></ref><ref id="hanspub.39644-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Marson, C.M. (2009) Histone Deacetylase Inhibitors: Design, Structure-Activity Relationships and Therapeutic Implications for Cancer. Anti-Cancer Agents in Medicinal Chemistry, 9, 661-692.  
https://doi.org/10.2174/187152009788679976</mixed-citation></ref><ref id="hanspub.39644-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Luan, Y., Li, J., Bernatchez, J.A., et al. (2019) Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy. Journal of Medicinal Chemistry, 62, 3171-3183. https://doi.org/10.1021/acs.jmedchem.8b00189</mixed-citation></ref><ref id="hanspub.39644-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Hess-Stumpp, H. (2005) Histone Deacetylase Inhibitors and Cancer: From Cell Biology to the Clinic. European Journal of Cell Biology, 84, 109-121. https://doi.org/10.1016/j.ejcb.2004.12.010</mixed-citation></ref><ref id="hanspub.39644-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Trapani, D., Esposito, A., Criscitiello, C., et al. (2017) Entinostat for the Treatment of Breast Cancer. Expert Opinion on Investigational Drugs, 26, 965-971. https://doi.org/10.1080/13543784.2017.1353077</mixed-citation></ref><ref id="hanspub.39644-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Fournel, M., Bonfils, C., Hou, Y., et al. (2008) MGCD0103, a Novel Isotype-Selective Histone Deacetylase Inhibitor, Has Broad Spectrum Antitumor Activity in Vitro and in Vivo. Molecular Cancer Therapeutics, 7, 759-768.  
https://doi.org/10.1158/1535-7163.MCT-07-2026</mixed-citation></ref><ref id="hanspub.39644-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Graziano, M.J., Spoon, T.A., Cockrell, E.A., et al. (2001) Induction of Apoptosis in Rat Peripheral Blood Lymphocytes by the Anticancer Drug CI-994 (Acetyldinaline). Journal of Biomedicine and Biotechnology, 1, 52-61.  
https://doi.org/10.1155/S1110724301000146</mixed-citation></ref><ref id="hanspub.39644-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Beckers, T., Burkhardt, C., Wieland, H., et al. (2007) Distinct Pharmacological Properties of Second Generation HDAC Inhibitors with the Benzamide or Hydroxamate Head Group. International Journal of Cancer, 121, 1138-1148.  
https://doi.org/10.1002/ijc.22751</mixed-citation></ref><ref id="hanspub.39644-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Henning, S.W. (2010) 178 Preclinical Characterization of 4SC-202, a Novel Isotype Specific HDAC Inhibitor. European Journal of Cancer—Supplement, 8, 61. https://doi.org/10.1016/S1359-6349(10)71883-8</mixed-citation></ref><ref id="hanspub.39644-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Peng, X., Liao, G., Sun, P., et al. (2019) An Overview of HDAC Inhibitors and Their Synthetic Routes. Current Topics in Medicinal Chemistry, 19, 1005-1040. https://doi.org/10.2174/1568026619666190227221507</mixed-citation></ref><ref id="hanspub.39644-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Ralph, M. (2015) Inhibitors of Histone Deacetylase. PCT International Application, 2015069693, May 14.</mixed-citation></ref><ref id="hanspub.39644-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Tang, S., Cheng, B., Zhe, N., et al. (2018) Histone Deacetylase Inhibitor BG45-Mediated HO-1 Expression Induces Apoptosis of Multiple Myeloma Cells by the JAK2/STAT3 Pathway. Anticancer Drugs, 29, 61-74.  
https://doi.org/10.1097/CAD.0000000000000568</mixed-citation></ref><ref id="hanspub.39644-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Malvaez, M., McQuown, S.C., Rogge, G.A., et al. (2013) HDAC3-Selective Inhibitor Enhances Extinction of Cocaine- Seeking Behavior in a Persistent Manner. Proceedings of the National Academy of Sciences of the United States of America, 110, 2647-2652. https://doi.org/10.1073/pnas.1213364110</mixed-citation></ref><ref id="hanspub.39644-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, M.J., Zhao, Q.C., Xia, M.X., et al. (2020) The HDAC3 Inhibitor RGFP966 Ameliorated Ischemic Brain Damage by Downregulating the AIM2 Inflammasome. The FASEB Journal, 34, 648-662.  
https://doi.org/10.1096/fj.201900394RRR</mixed-citation></ref><ref id="hanspub.39644-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Wagner, F.F., Lundh, M., Kaya, T., et al. (2016) An Isochemogenic Set of Inhibitors to Define the Therapeutic Potential of Histone Deacetylases in β-Cell Protection. ACS Chemical Biology, 11, 363-374.  
https://doi.org/10.1021/acschembio.5b00640</mixed-citation></ref><ref id="hanspub.39644-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Wagner, F.F., Zhang, Y.L., Fass, D.M., et al. (2015) Kinetically Selective Inhibitors of Histone Deacetylase 2 (HDAC2) as Cognition Enhancers. Chemical Science, 6, 804-815. https://doi.org/10.1039/C4SC02130D</mixed-citation></ref><ref id="hanspub.39644-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Hirata, Y., Sasaki, T., Kanki, H., et al. (2018) New 5-Aryl-Substituted 2-Aminobenzamide-Type HDAC Inhibitors with a Diketopiperazine Group and Their Ameliorating Effects on Ischemia-Induced Neuronal Cell Death. Scientific Reports, 8, Article No. 1400. https://doi.org/10.1038/s41598-018-19664-9</mixed-citation></ref><ref id="hanspub.39644-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Mendoza-Sanchez, R., Cotnoir-White, D., Kulpa, J., et al. (2015) Design, Synthesis and Evaluation of Antiestrogen and Histone Deacetylase Inhibitor Molecular Hybrids. Bioorganic &amp; Medicinal Chemistry, 23, 7597-7606.  
https://doi.org/10.1016/j.bmc.2015.11.005</mixed-citation></ref><ref id="hanspub.39644-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Boissinot, M., Inman, M., Hempshall, A., et al. (2012) Induction of Differentiation and Apoptosis in Leukaemic Cell Lines by the Novel Benzamide Family Histone Deacetylase 2 and 3 Inhibitor MI-192. Leukemia Research, 36, 1304-1310.  
https://doi.org/10.1016/j.leukres.2012.07.002</mixed-citation></ref><ref id="hanspub.39644-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Eyre, T.A., Collins, G.P., Gupta, A., et al. (2019) A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of CXD101 in Patients with Advanced Cancer. Cancer, 125, 99-108. https://doi.org/10.1002/cncr.31791</mixed-citation></ref><ref id="hanspub.39644-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Poli, G., Di Fabio, R., Ferrante, L., et al. (2017) Largazole Analogues as Histone Deacetylase Inhibitors and Anticancer Agents: An Overview of Structure-Activity Relationships. ChemMedChem, 12, 1917-1926.  
https://doi.org/10.1002/cmdc.201700563</mixed-citation></ref><ref id="hanspub.39644-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Ma, N., Luo, Y., Wang, Y., et al. (2016) Selective Histone Deacetylase Inhibitors with Anticancer Activity. Current Topics in Medicinal Chemistry, 16, 415-426. https://doi.org/10.2174/1568026615666150813145629</mixed-citation></ref><ref id="hanspub.39644-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Parlet, C.P., Kavanaugh, J.S., Crosby, H.A., et al. (2019) Apicidin Attenuates MRSA Virulence through Quorum-Sensing Inhibition and Enhanced Host Defense. Cell Reports, 27, 187-198.e6.  
https://doi.org/10.1016/j.celrep.2019.03.018</mixed-citation></ref><ref id="hanspub.39644-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Arts, J., King, P., Mariën, A., et al. (2009) JNJ-26481585, a Novel “Second-Generation” Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity. Clinical Cancer Research, 15, 6841-6851.  
https://doi.org/10.1158/1078-0432.CCR-09-0547</mixed-citation></ref><ref id="hanspub.39644-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Su, G.H., Sohn, T.A., Ryu, B., et al. (2000) A Novel Histone Deacetylase Inhibitor Identified by High-Throughput Transcriptional Screening of a Compound Library. Cancer Research, 60, 3137-3142.</mixed-citation></ref><ref id="hanspub.39644-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Sharma, V., Koul, N., Joseph, C., et al. (2010) HDAC Inhibitor, Scriptaid, Induces Glioma Cell Apoptosis through JNK Activation and Inhibits Telomerase Activity. Journal of Cellular and Molecular Medicine, 14, 2151-2161.  
https://doi.org/10.1111/j.1582-4934.2009.00844.x</mixed-citation></ref><ref id="hanspub.39644-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Wood, T.E., Dalili, S., Simpson, C.D., et al. (2010) Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands. Molecular Cancer Therapeutics, 9, 246-256.  
https://doi.org/10.1158/1535-7163.MCT-09-0495</mixed-citation></ref><ref id="hanspub.39644-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">McCourt, C., Maxwell, P., Mazzucchelli, R., et al. (2012) Elevation of c-FLIP in Castrate-Resistant Prostate Cancer Antagonizes Therapeutic Response to Androgen Receptor-Targeted Therapy. Clinical Cancer Research, 18, 3822-3833.  
https://doi.org/10.1158/1078-0432.CCR-11-3277</mixed-citation></ref><ref id="hanspub.39644-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Balasubramanian, S., Ramos, J., Luo, W., et al. (2008) A Novel Histone Deacetylase 8 (HDAC8)-Specific Inhibitor PCI-34051 Induces Apoptosis in T-Cell Lymphomas. Leukemia, 22, 1026-1034. https://doi.org/10.1038/leu.2008.9</mixed-citation></ref><ref id="hanspub.39644-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Suzuki, T., Muto, N., Bando, M., et al. (2014) Design, Synthesis, and Biological Activity of NCC149 Derivatives as Histone Deacetylase 8-Selective Inhibitors. ChemMedChem, 9, 657-664. https://doi.org/10.1002/cmdc.201300414</mixed-citation></ref><ref id="hanspub.39644-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Tng, J., Lim, J., Wu, K.C., et al. (2020) Achiral Derivatives of Hydroxamate AR-42 Potently Inhibit Class I HDAC Enzymes and Cancer Cell Proliferation. Journal of Medicinal Chemistry, 63, 5956-5971.  
https://doi.org/10.1021/acs.jmedchem.0c00230</mixed-citation></ref><ref id="hanspub.39644-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Hassan, M.M., Israelian, J., Nawar, N., et al. (2020) Characterization of Conformationally Constrained Benzanilide Scaffolds for Potent and Selective HDAC8 Targeting. Journal of Medicinal Chemistry, 63, 8634-8648.  
https://doi.org/10.1021/acs.jmedchem.0c01025</mixed-citation></ref><ref id="hanspub.39644-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Yang, Y.C., Chen, C.N., Wu, C.I., et al. (2013) NBM-T-L-BMX-OS01, Semisynthesized from Osthole, Is a Novel Inhibitor of Histone Deacetylase and Enhances Learning and Memory in Rats. Evidence-Based Complementary and Alternative Medicine, 2013, Article ID: 514908. https://doi.org/10.1155/2013/514908</mixed-citation></ref><ref id="hanspub.39644-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Moffat, D., Patel, S., Day, F., et al. (2010) Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex- 3-yl)-N-hydroxypyrim Idine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor. Journal of Medicinal Chemistry, 53, 8663-8678. https://doi.org/10.1021/jm101177s</mixed-citation></ref><ref id="hanspub.39644-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Marek, L., Hamacher, A., Hansen, F.K., et al. (2013) Histone Deacetylase (HDAC) Inhibitors with a Novel Connecting Unit Linker Region Reveal a Selectivity Profile for HDAC4 and HDAC5 with Improved Activity against Chemoresistant Cancer Cells. Journal of Medicinal Chemistry, 56, 427-436. https://doi.org/10.1021/jm301254q</mixed-citation></ref><ref id="hanspub.39644-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Di Giorgio, E., Gagliostro, E. and Brancolini, C. (2015) Selective Class IIa HDAC Inhibitors: Myth or Reality. Cellular and Molecular Life Sciences, 72, 73-86. https://doi.org/10.1007/s00018-014-1727-8</mixed-citation></ref><ref id="hanspub.39644-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Olsson, A., Björk, A., Vallon-Christersson, J., et al. (2010) Tasquinimod (ABR-215050), a Quinoline-3-Carboxamide Anti-Angiogenic Agent, Modulates the Expression of Thrombospondin-1 in Human Prostate Tumors. Molecular Cancer, 9, 107. https://doi.org/10.1186/1476-4598-9-107</mixed-citation></ref><ref id="hanspub.39644-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Mai, A., Massa, S., Pezzi, R., et al. (2005) Class II (IIa)-Selective Histone Deacetylase Inhibitors. 1. Synthesis and Biological Evaluation of Novel (Aryloxopropenyl)pyrrolyl Hydroxyamides. Journal of Medicinal Chemistry, 48, 3344-3353. https://doi.org/10.1021/jm049002a</mixed-citation></ref><ref id="hanspub.39644-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Butler, K.V., Kalin, J., Brochier, C., et al. (2010) Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A. Journal of the American Chemical Society, 132, 10842-10846.  
https://doi.org/10.1021/ja102758v</mixed-citation></ref><ref id="hanspub.39644-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Haggarty, S.J., Koeller, K.M., Wong, J.C., et al. (2003) Domain-Selective Small-Molecule Inhibitor of Histone Deacetylase 6 (HDAC6)-Mediated Tubulin Deacetylation. Proceedings of the National Academy of Sciences of the United States of America, 100, 4389-4394. https://doi.org/10.1073/pnas.0430973100</mixed-citation></ref><ref id="hanspub.39644-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Tan, J., Cang, S., Ma, Y., et al. (2010) Novel Histone Deacetylase Inhibitors in Clinical Trials as Anti-Cancer Agents. Journal of Hematology &amp; Oncology, 3, 5. https://doi.org/10.1186/1756-8722-3-5</mixed-citation></ref><ref id="hanspub.39644-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Jochems, J., Boulden, J., Lee, B.G., et al. (2014) Antidepressant-Like Properties of Novel HDAC6-Selective Inhibitors with Improved Brain Bioavailability. Neuropsychopharmacology, 39, 389-400. https://doi.org/10.1038/npp.2013.207</mixed-citation></ref><ref id="hanspub.39644-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Kozikowski, A.P., Tapadar, S., Luchini, D.N., et al. (2008) Use of the Nitrile Oxide Cycloaddition (NOC) Reaction for Molecular Probe Generation: A New Class of Enzyme Selective Histone Deacetylase Inhibitors (HDACIs) Showing Picomolar Activity at HDAC6. Journal of Medicinal Chemistry, 51, 4370-4373. https://doi.org/10.1021/jm8002894</mixed-citation></ref><ref id="hanspub.39644-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Lee, J.H., Mahendran, A., Yao, Y., et al. (2013) Development of a Histone Deacetylase 6 Inhibitor and Its Biological Effects. Proceedings of the National Academy of Sciences of the United States of America, 110, 15704-15709.  
https://doi.org/10.1073/pnas.1313893110</mixed-citation></ref><ref id="hanspub.39644-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Bergman, J.A., Woan, K., Perez-Villarroel, P., et al. (2012) Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth. Journal of Medicinal Chemistry, 55, 9891-9899.  
https://doi.org/10.1021/jm301098e</mixed-citation></ref><ref id="hanspub.39644-ref53"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">Hideshima, T., Qi, J., Paranal, R.M., et al. (2016) Discovery of Selective Small-Molecule HDAC6 Inhibitor for Overcoming Proteasome Inhibitor Resistance in Multiple Myeloma. Proceedings of the National Academy of Sciences of the United States of America, 113, 13162-13167. https://doi.org/10.1073/pnas.1608067113</mixed-citation></ref><ref id="hanspub.39644-ref54"><label>54</label><mixed-citation publication-type="other" xlink:type="simple">Inks, E.S., Josey, B.J., Jesinkey, S.R., et al. (2012) A Novel Class of Small Molecule Inhibitors of HDAC6. ACS Chemical Biology, 7, 331-339. https://doi.org/10.1021/cb200134p</mixed-citation></ref><ref id="hanspub.39644-ref55"><label>55</label><mixed-citation publication-type="other" xlink:type="simple">Wagner, F.F., Olson, D.E., Gale, J.P., et al. (2013) Potent and Selective Inhibition of Histone Deacetylase 6 (HDAC6) Does Not Require a Surface-Binding Motif. Journal of Medicinal Chemistry, 56, 1772-1776.  
https://doi.org/10.1021/jm301355j</mixed-citation></ref><ref id="hanspub.39644-ref56"><label>56</label><mixed-citation publication-type="other" xlink:type="simple">Kozikowski, A.P., Shen, S., Pardo, M., et al. (2019) Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome. ACS Chemical Neuroscience, 10, 1679-1695. https://doi.org/10.1021/acschemneuro.8b00600</mixed-citation></ref><ref id="hanspub.39644-ref57"><label>57</label><mixed-citation publication-type="other" xlink:type="simple">Shen, S., Hadley, M., Ustinova, K., et al. (2019) Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models. Journal of Medicinal Chemistry, 62, 8557-8577. https://doi.org/10.1021/acs.jmedchem.9b00946</mixed-citation></ref><ref id="hanspub.39644-ref58"><label>58</label><mixed-citation publication-type="other" xlink:type="simple">Vergani, B., Sandrone, G., Marchini, M., et al. (2019) Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation. Journal of Medicinal Chemistry, 62, 10711-10739. https://doi.org/10.1021/acs.jmedchem.9b01194</mixed-citation></ref><ref id="hanspub.39644-ref59"><label>59</label><mixed-citation publication-type="other" xlink:type="simple">Martin, M.W., Lee, J.Y., Lancia, D.R., et al. (2018) Discovery of Novel N-Hydroxy-2-Arylisoindoline-4-Carbox- amides as Potent and Selective Inhibitors of HDAC11. Bioorganic &amp; Medicinal Chemistry Letters, 28, 2143-2147.  
https://doi.org/10.1016/j.bmcl.2018.05.021</mixed-citation></ref><ref id="hanspub.39644-ref60"><label>60</label><mixed-citation publication-type="other" xlink:type="simple">Son, S.I., Cao, J., Zhu, C.L., et al. (2019) Activity-Guided Design of HDAC11-Specific Inhibitors. ACS Chemical Biology, 14, 1393-1397. https://doi.org/10.1021/acschembio.9b00292</mixed-citation></ref></ref-list></back></article>